State Treasurer State of Michigan boosted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,600 shares of the medical research company’s stock after buying an additional 200 shares during the period. State Treasurer State of Michigan’s holdings in Bio-Rad Laboratories were worth $1,946,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BIO. BlackRock Inc. increased its position in shares of Bio-Rad Laboratories by 9,953.4% in the first quarter. BlackRock Inc. now owns 1,733,111 shares of the medical research company’s stock valued at $345,478,000 after buying an additional 1,715,872 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Bio-Rad Laboratories by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,673,274 shares of the medical research company’s stock valued at $333,550,000 after buying an additional 58,774 shares in the last quarter. TimesSquare Capital Management LLC increased its position in Bio-Rad Laboratories by 17.2% in the first quarter. TimesSquare Capital Management LLC now owns 611,700 shares of the medical research company’s stock valued at $121,936,000 after buying an additional 89,800 shares during the period. Alliancebernstein L.P. increased its position in Bio-Rad Laboratories by 1.7% in the first quarter. Alliancebernstein L.P. now owns 335,197 shares of the medical research company’s stock valued at $66,818,000 after buying an additional 5,647 shares during the period. Finally, Fisher Asset Management LLC increased its position in Bio-Rad Laboratories by 1.9% in the second quarter. Fisher Asset Management LLC now owns 279,589 shares of the medical research company’s stock valued at $63,274,000 after buying an additional 5,233 shares during the period. 63.73% of the stock is owned by institutional investors.

Bio-Rad Laboratories, Inc. (BIO) traded up 0.41% during mid-day trading on Friday, reaching $215.89. 232,899 shares of the company were exchanged. Bio-Rad Laboratories, Inc. has a 1-year low of $147.68 and a 1-year high of $242.79. The company has a 50 day moving average of $229.16 and a 200-day moving average of $212.40. The company has a market capitalization of $6.40 billion, a price-to-earnings ratio of 426.66 and a beta of 0.91.

ILLEGAL ACTIVITY NOTICE: “State Treasurer State of Michigan Has $1.95 Million Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/08/12/state-treasurer-state-of-michigan-increases-stake-in-bio-rad-laboratories-inc-nysebio-updated.html.

Several research analysts have commented on BIO shares. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Jefferies Group LLC reissued a “buy” rating and set a $275.00 price objective on shares of Bio-Rad Laboratories in a report on Friday, July 14th. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 target price on the stock. Finally, Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and decreased their target price for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Bio-Rad Laboratories has an average rating of “Buy” and an average target price of $228.80.

In related news, EVP Michael Crowley sold 700 shares of the firm’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $215.91, for a total value of $151,137.00. Following the transaction, the executive vice president now owns 2,060 shares in the company, valued at $444,774.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 28.29% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.